» Articles » PMID: 30221696

LIMD2 Targeted by MiR‑34a Promotes the Proliferation and Invasion of Non‑small Cell Lung Cancer Cells

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2018 Sep 18
PMID 30221696
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

A previous study indicated that LIM domain containing 2 (LIMD2) is an oncogene in a variety of human cancers, including breast, bladder and thyroid cancers, and melanoma; however, the role of LIMD2 in non‑small cell lung cancer (NSCLC) remains largely unknown. In the present study, by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis, it was demonstrated that LIMD2 was significantly upregulated in NSCLC tissues compared with adjacent normal tissues. Consistently, LIMD2 was also upregulated in NSCLC cell lines. Furthermore, the present study reported that knockdown of LIMD2 significantly inhibited the proliferation and invasion of H1299 and A549 cells by Cell Counting Kit‑8 and Transwell assays. In addition, the expression of LIMD2 was determined to be regulated by microRNA (miR)‑34a in the present study. RT‑qPCR and western blot analysis indicated that overexpression of miR‑34a notably reduced the mRNA and protein expression levels of LIMD2 in H1299 and H549 cells. Additionally, the present study reported an inverse correlation between the expression of LIMD2 and miR‑34a in NSCLC tissues. A luciferase reporter assay also demonstrated that miR‑34a directly targeted the mRNA expression of LIMD2 in NSCLC cells. Finally, miR‑34a was revealed to possess a tumor suppressive role in NSCLC cells. Collectively, the results of the present study revealed that LIMD2 promoted NSCLC progression and was regulated by miR‑34a.

Citing Articles

Fungal protein D1 inhibits the proliferation of A549 cells via activating the p53/miR-34a signaling pathway.

Zhang M, Liu F, Gao W, Liu Z J Nat Med. 2025; .

PMID: 39966243 DOI: 10.1007/s11418-024-01869-0.


Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo.

Li J, Zhong X, Zhao Y, Shen J, Xiao Z, Pilapong C Sci Rep. 2024; 14(1):2348.

PMID: 38287075 PMC: 10824707. DOI: 10.1038/s41598-024-52896-6.


Knockdown of LIMD2 inhibits the progression of ovarian carcinoma through ERK1/2 pathway.

Hu H, Wang Y, Dong Y, Wang L, Chen Y, Zhou Y Mol Biol Rep. 2023; 50(11):8985-8993.

PMID: 37716918 DOI: 10.1007/s11033-023-08733-6.


Analysis of cuproptosis-related genes in Ulcerative colitis and immunological characterization based on machine learning.

Wang Z, Wang Y, Yan J, Wei Y, Zhang Y, Wang X Front Med (Lausanne). 2023; 10:1115500.

PMID: 37529244 PMC: 10389668. DOI: 10.3389/fmed.2023.1115500.


Low-Dose Apatinib Improves the Prognosis of Patients with Recurrent High-Grade Gliomas.

Zhang M, Gao L, Liu X, Dong F, Su Q, Zhang Y Evid Based Complement Alternat Med. 2022; 2022:3181133.

PMID: 36106030 PMC: 9467810. DOI: 10.1155/2022/3181133.